Header Logo

Connection

Robin Jones to Imatinib Mesylate

This is a "connection" page, showing publications Robin Jones has written about Imatinib Mesylate.
Connection Strength

0.797
  1. KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment. Chemotherapy. 2022; 67(2):81-90.
    View in: PubMed
    Score: 0.195
  2. Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. Eur J Surg Oncol. 2021 08; 47(8):2173-2181.
    View in: PubMed
    Score: 0.185
  3. Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors. Future Oncol. 2020 Aug; 16(22):1639-1646.
    View in: PubMed
    Score: 0.175
  4. p.(L576P) -KIT mutation in GIST: Favorable prognosis and sensitive to imatinib? Cancer Biol Ther. 2016 05 03; 17(5):543-5.
    View in: PubMed
    Score: 0.130
  5. The development and application of imatinib. Expert Opin Drug Saf. 2005 Mar; 4(2):183-91.
    View in: PubMed
    Score: 0.061
  6. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clin Cancer Res. 2022 04 14; 28(8):1672-1679.
    View in: PubMed
    Score: 0.050
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.